Divi’s Laboratories reported a consolidated total income of ₹2860 crores for Q2 FY26, up from ₹2444 crores in the corresponding period of the previous year. Profit before tax reached ₹912 crores. Additionally, Mr. Nimmagadda Venkata Anirudh has been appointed as President (Nutraceuticals), effective November 7, 2025, heading the company’s nutraceutical business.
Financial Performance
Divi’s Laboratories announced a strong financial performance for Q2 FY26. Key highlights include:
- Consolidated total income: ₹2860 crores (up from ₹2444 crores)
- Profit before tax: ₹912 crores
- Profit after tax: ₹689 Crores
- Forex gain: ₹63 crores
For the half year ended September 30, 2025, the company reported a consolidated total income of ₹5389 crores as against ₹4640 crores in the corresponding period. PBT reached ₹1645 crores and PAT stood at ₹1234 crores. The company also reported a forex gain of ₹102 crores for the half-year.
Senior Management Appointment
The company announced the appointment of Mr. Nimmagadda Venkata Anirudh as President (Nutraceuticals) and Senior Management Personnel, effective November 07, 2025. He will lead the nutraceutical business and report directly to the Chief Executive Officer.
Mr. Anirudh’s profile includes:
- Experience: Joined Divi’s Laboratories in 2014, previously held roles including Relationship Manager.
- Responsibilities: Maximize sales potential for nutraceutical ingredients, identify new ingredients, improve operational efficiencies, and oversee subsidiaries in the USA and Switzerland.
It was also noted that Mr. Anirudh is the son of Mr. N.V. Ramana, Executive Director of the Company.
Source: BSE
